Email Updates

Search form

You are here

AVAC's Blog: P-Values

  • Rob Newells, Executive Director for the AIDS Project of the East Bay, reports back on what caught his attention at the Conference on Retroviruses and Opportunistic Infections and his experience as one of very few African America attendees.

    April 24, 2017
    Antibody Related Research, Cure, PrEP
    Rob Newells
  • In April, countries across Africa review and finalize their annual PEPFAR-supported HIV programs. AVAC joined Health Gap and MSMGF to support and prepare MSM advocates attending the reviews.

    April 20, 2017
  • In this piece, Udom Likhitwonnawut, a long-time advocate for community engagement in HIV research in Thailand, argues in favor of PrEP in Thailand.

    April 20, 2017
    Udom Likhitwonnawut
  • Julie Patterson, an HIV prevention research advocate, discusses her experience earlier this year at the Conference on Retroviruses and Opportunistic Infections (CROI). Initially encouraged by programming geared toward advocate, she came away disappointed, wondering if researchers were listening.

    April 20, 2017
    Antibody Related Research, General
    Julie Patterson
  • This year will mark the 20th anniversary of HIV Vaccine Awareness Day (HVAD). On this May 18, as HIV prevention advocates we find ourselves in new terrain when it comes to vaccine research—both in terms of scientific progress and the challenging political environment. And read on for a range of HVAD tools and resources for the day and for year-round vaccine advocacy.

    April 20, 2017
  • How many doses of oral PrEP must be taken to build up protective levels of drug in the blood? In a webinar, representatives from the CDC and WHO will review their respective guidance development processes and the role, use, contexts and audience for guidance documents. Recording now available.

    April 4, 2017
  • AMP. Licensure. Enrollment targets. Success. These were the buzz words from the HIV Vaccine Trials Network regional meeting last month, highlighting the HVTN’s build out of programs in sub-Saharan Africa and the significance of an HIV vaccine for this region.

    March 21, 2017
    Ruth Assefa
    Stacey Hannah
  • We've posted several new resources on that you won’t want to miss—analysis of the WHO's recently released guidance on the use of hormonal contraceptives in women at risk of HIV, information about time to protection for PrEP and a blog on building solidarity between African American gay men and African gay men through PrEP.

    March 20, 2017
  • Despite decades of advances in HIV prevention, HIV continues to burden gay and bisexual men disproportionately, especially younger gay men, and men who have sex with men. This is truly a global health issue—applying equally to the US and to Africa. Vulnerability to HIV exposure is propelled by key structural drivers: antigay stigma laws, poverty and inadequate understanding of how to prevent HIV.

    March 17, 2017
    Micheal Ighodaro
  • The WHO issued an updated guidance statement on its recommendations for the use of hormonal contraception by women at high risk of HIV. The update changes the WHO classification of long-acting injectable contraceptives. WHO states “there continues to be evidence of a possible increased risk of HIV among progestogen-only injectable users.” The new guidance is clear that the recommendations are based on women’s right to informed choice in health.

    March 2, 2017